VivoSeq
0

Pipeline Programs

11

Active Trials

24

Companies Involved

Lip is an early-stage landscape with 0 programs across 24 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Merck & Co., Novartis.

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

160

clinical trials

Completed119 · 74%
Unknown status13 · 8%
Terminated11 · 7%
Recruiting7 · 4%
Withdrawn6 · 4%
Not yet recruiting2 · 1%
Other2 · 1%

Trial Activity

160 trials

Regional Lipolysis Insulin Regulation
Recruiting·MMayo Clinic·Phase 1·NCT06392854·48 enrolled
Insulin Regulation of Lipolysis and Lipolysis Proteins
Recruiting·MMayo Clinic·Phase 1·NCT03866408·64 enrolled
Got Doxy- 'Flipping the Script' on STI PEP
Recruiting·EEmory University·Phase 4·NCT07215325·200 enrolled
Lipoic Acid Supplement for Cystine Stone
Active, not recruiting··Phase 2·NCT02910531·50 enrolled
Effects of Sitagliptin in Relatives of T1D Patients
Not yet recruiting·UUniversity of Milan·Phase 2/3·NCT05219409·70 enrolled
MK-0524B Lipid Study (MK-0524B-063)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00479882·2,414 enrolled
Study of Multiple Doses of Saxagliptin (BMS-477118)
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00950599·423 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)